Vera Therapeutics Q3 net loss $24.7M; cash $114.4M; atacicept Ph2b ORIGIN data early Q1 2023

Vera Therapeutics, Inc.

2022-Q3 EPS reported -$2.16

Net loss of $24.7M ($0.91 per share) vs $7.6M loss YoY; cash burn $46.4M YTD.
Cash, equivalents, and marketable securities $114.4M; additional $20M drawn from credit facility in Nov 2022; funds operations to Q2 2024.
Phase 2b ORIGIN trial of atacicept in IgA nephropathy topline data expected early Q1 2023.
Initiated pivotal Phase 3 COMPASS trial of atacicept in lupus nephritis.
Positive Phase 2 MAU868 results in BK viremia presented; plan to start Ph2b/Ph3 trial in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vera Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income a net loss of $24.7 million, or a net loss per diluted share of $0.91, EPS $0.91.

Period: the quarter ended September 30, 2022
Net income: a net loss of $24.7 million, or a net loss per diluted share of $0.91
EPS: $0.91
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, the company reported a net loss of $24.7 million, or a net loss per diluted share of $0.91, compared to a net loss of $7.6 million, or a net loss per diluted share of $0.36, for the same period last year.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.